News & analysis, rated.
Breaking AI developments, in-depth guides, real-world case studies, and analysis — each one rated so you know what matters.
India completes nationwide rollout of Ayushman Bharat health scheme with West Bengal
West Bengal became the 36th state to join PM-JAY on June 9, completing universal coverage. The scheme has funded 12 crore treatments worth Rs 1.82 lakh crore since 2018.
Air pollution damages placenta, cuts fetal growth in AIIMS study
AIIMS Delhi found PM2.5 and PM10 particles cross the placental barrier, triggering inflammation that restricts fetal development and increases low birth weight risk. The study identified toxic metals and a suppressed growth gene.
Haleon invests ₹2,000 crore in first Indian manufacturing plant
Haleon is building a 40-acre automated facility in Madhya Pradesh expected to open by 2029–30, creating 500 direct jobs. Why the maker of Sensodyne is betting on India now.
Indian study links vitamin D, B12 deficiency to higher dementia risk
ICMR-NIN research of 570 adults found 40% had elevated dementia risk scores, with vitamin D, B2, B6, and B12 deficiencies far more common in the higher-risk group. The findings point to nutrition as a modifiable prevention target.
76% of clinical trials need protocol rewrites—AI can predict them upfront
Static trial protocols drive costly amendments months into execution. Machine learning trained on real trial data can now flag design flaws before enrollment starts, cutting delays and site burden.
J&J buys Firefly for $1B to merge protein degraders with antibody drugs
Johnson & Johnson is acquiring Firefly Biotech for $1 billion to gain access to a hybrid drug platform combining protein degraders and antibody-drug conjugates. Here's what the combo technology does.
Incyte to buy Vega for $2B blood disorder drug in late-stage trials
Incyte is acquiring Vega Therapeutics, a spinoff from Star Biotech, for roughly $2B to add a bleeding-control medicine in late-stage development. What the deal signals about pharma M&A in biotech.
Tango's pancreatic cancer combo lifts response rates in early trial
Tango Therapeutics' experimental drug combination showed response rates well above historical expectations in a small clinical trial, sending shares higher. Early data raises questions about potential efficacy in a field with limited treatment options.
Roche bets $700M that protein-degrading drugs beat enzyme blockers
Roche is investing $700 million upfront in Nurix's BTK protein degrader, with potential total value reaching $2.3 billion. The bet hinges on whether destroying the enzyme outperforms existing drugs that merely inhibit it.
City Therapeutics raises $100M for RNA drugs backed by Alnylam founder
City Therapeutics, co-founded by former Alnylam CEO John Maraganore, secured nearly $100M in Series B funding. The biotech is advancing an RNAi drug for a blood clotting disorder into human trials, with a Stargardt disease candidate in the pipeline.
Boston Scientific builds Indiana hub for global device distribution
Boston Scientific is constructing a distribution center in Indiana near a principal manufacturing facility to handle global shipments of its medical devices. The move consolidates logistics operations.
Three diabetes device makers present data at ADA conference
Tandem Diabetes Care, Insulet, and Dexcom showed new findings at the American Diabetes Association's Scientific Sessions. What each company revealed and why it matters for patients.